Somnus Therapeutics Licenses Sleep Candidate From SkyePharma
This article was originally published in The Pink Sheet Daily
Executive Summary
Somnus will pay SkyePharma up to $35 million in milestones for development of the non-benzodiazepine sleep therapy.